Prescription Appropriateness of Cyproterone Acetate/Ethinylestradiol in Primary Care: A Population-Based Study in Italy

Overview

Journal Clin Drug Investig

Date 2017 Apr 24

PMID 28434141

Authors

Francesco Lapi

Monica Simonetti

Iacopo Cricelli

Claudio Cricelli

Nicoletta Cassano

Gino A Vena

Affiliations

Soon will be listed here.

Abstract

Background And Objective: We evaluated the prescription appropriateness of cyproterone acetate in combination with ethinylestradiol (CPA/EE) in a primary care setting before and after the 2013 European Medicines Agency's (EMA) recommendation relating to the risk profile of CPA/EE.

Methods: Data were obtained from the Health Search IMS Health Longitudinal Patient Database (HSD). We compared the results from 2011 to 2012 with the results of 2014, namely before and after the 2013 EMA recommendation, and investigated the burden of concurrent use of CPA/EE and other hormonal contraceptives (HCs) and the reported indication at the time of CPA/EE prescription.

Results: Overall, 1189 new users of CPA/EE were identified: 495 in 2011, 446 in 2012, and 261 in 2014. Concomitant use of CPA/EE and other HCs was found in 1% of cases in 2011-2012 and 2% of cases in 2014, while potential concomitant use was observed in 4% of cases in 2011 and 2% of cases in 2012 and 2014. A recent (within 365 days) diagnosis of any hyperandrogenic condition was detected in 22 and 24% of CPA/EE users in 2011 and 2012, respectively, and in 24% of cases in 2014. The percentage of CPA/EE users with a recent acne diagnosis and/or treatment was 19, 21, and 18% in 2011, 2012, and 2014, respectively.

Conclusions: Apart from an overall reduction in CPA/EE prescriptions in the HSD, no substantial difference was found in terms of the proportions of patients diagnosed with acne or other hyperandrogenic conditions and/or potential concomitant use of HCs before and after the EMA recommendation.

References

Seaman H, de Vries C, Farmer R . The risk of venous thromboembolism in women prescribed cyproterone acetate in combination with ethinyl estradiol: a nested cohort analysis and case-control study. Hum Reprod. 2003; 18(3):522-6. DOI: 10.1093/humrep/deg120. View

Vena G, Altomare G, Ayala F, Berardesca E, Calzavara-Pinton P, Chimenti S . Incidence of psoriasis and association with comorbidities in Italy: a 5-year observational study from a national primary care database. Eur J Dermatol. 2010; 20(5):593-8. DOI: 10.1684/ejd.2010.1017. View

Filippi A, Vanuzzo D, Bignamini A, Mazzaglia G, Cricelli C, Catapano A . The database of Italian general practitioners allows a reliable determination of the prevalence of myocardial infarction. Ital Heart J. 2005; 6(4):311-4. View

Cea-Soriano L, Wallander M, Rodriguez L . Prescribing patterns of combined hormonal products containing cyproterone acetate, levonorgestrel and drospirenone in the UK. J Fam Plann Reprod Health Care. 2016; 42(4):247-254. DOI: 10.1136/jfprhc-2015-101202. View

de Bastos M, Stegeman B, Rosendaal F, van Hylckama Vlieg A, Helmerhorst F, Stijnen T . Combined oral contraceptives: venous thrombosis. Cochrane Database Syst Rev. 2014; (3):CD010813. PMC: 10637279. DOI: 10.1002/14651858.CD010813.pub2. View

Franks S, Layton A, Glasier A . Cyproterone acetate/ethinyl estradiol for acne and hirsutism: time to revise prescribing policy. Hum Reprod. 2007; 23(2):231-2. DOI: 10.1093/humrep/dem379. View

Mazzaglia G, Ambrosioni E, Alacqua M, Filippi A, Sessa E, Immordino V . Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients. Circulation. 2009; 120(16):1598-605. DOI: 10.1161/CIRCULATIONAHA.108.830299. View

Stegeman B, de Bastos M, Rosendaal F, van Hylckama Vlieg A, Helmerhorst F, Stijnen T . Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta-analysis. BMJ. 2013; 347:f5298. PMC: 3771677. DOI: 10.1136/bmj.f5298. View

Dinger J, Bardenheuer K, Heinemann K . Cardiovascular and general safety of a 24-day regimen of drospirenone-containing combined oral contraceptives: final results from the International Active Surveillance Study of Women Taking Oral Contraceptives. Contraception. 2014; 89(4):253-63. DOI: 10.1016/j.contraception.2014.01.023. View

10.

Kant A, van Puijenbroek E, van Hunsel F . Reflections after the Diane affair. J Thromb Haemost. 2014; 12(9):1385-7. DOI: 10.1111/jth.12622. View

11.

Cricelli C, Mazzaglia G, Samani F, Marchi M, Sabatini A, Nardi R . Prevalence estimates for chronic diseases in Italy: exploring the differences between self-report and primary care databases. J Public Health Med. 2003; 25(3):254-7. DOI: 10.1093/pubmed/fdg060. View

12.

Lidegaard O, Lokkegaard E, Jensen A, Skovlund C, Keiding N . Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med. 2012; 366(24):2257-66. DOI: 10.1056/NEJMoa1111840. View

13.

Barnett C, Hagemann C, Dinger J, Minh T, Heinemann K . Fertility and combined oral contraceptives - unintended pregnancies and planned pregnancies following oral contraceptive use - results from the INAS-SCORE study. Eur J Contracept Reprod Health Care. 2016; 22(1):17-23. DOI: 10.1080/13625187.2016.1241991. View

14.

Soriano L, Asiimwe A, Garcia Rodriguez L . Prescribing of cyproterone acetate/ethinylestradiol in UK general practice: a retrospective descriptive study using The Health Improvement Network. Contraception. 2016; 95(3):299-305. DOI: 10.1016/j.contraception.2016.10.003. View

15.

Bezemer I, Verhamme K, Gini R, Mosseveld M, Rijnbeek P, Trifiro G . Use of oral contraceptives in three European countries: a population-based multi-database study. Eur J Contracept Reprod Health Care. 2015; 21(1):81-7. DOI: 10.3109/13625187.2015.1102220. View